- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma, Metastatic Non-Cutaneous Melanoma, Non-Cutaneous Melanoma, Recurrent Cutaneous Melanoma, Recurrent Mucosal Melanoma, Recurrent Non-Cutaneous Melanoma
- Interventions
- Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b
- Procedure · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1,301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 552
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 379 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 545
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Melanoma (Skin)
- Interventions
- aldesleukin, filgrastim, recombinant interferon alfa, cisplatin, dacarbazine, vinblastine
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 482 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 94
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
- Conditions
- Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
- Interventions
- Bevacizumab, Irinotecan Hydrochloride, Temozolomide
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 93
- States / cities
- Mobile, Alabama • Fairbanks, Alaska • Scottsdale, Arizona + 73 more
- Conditions
- Osteoarthritis of the Knee
- Interventions
- NKTR-181, Placebo
- Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 34
- States / cities
- Mobile, Alabama • Tucson, Arizona • Garden Grove, California + 29 more
- Conditions
- Cancer-related Problem/Condition, Head and Neck Cancer, Pain
- Interventions
- glutamine, radiation therapy, l-glutamine placebo
- Dietary Supplement · Radiation · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 106
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 68 more
- Conditions
- Aphasia, CVA, Apraxia of Speech
- Interventions
- Sound Production Treatment (SPT)
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Salt Lake City, Utah
- Conditions
- Acute Renal Failure, Kidney Disease, Coronary Artery Disease
- Interventions
- IV isotonic saline, IV isotonic bicarbonate, N-acetylcysteine, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 5,177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 35
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 32 more
- Conditions
- Migraine
- Interventions
- Ubrogepant, Placebo for Ubrogepant
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 496 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 103
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 92 more
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage IVB Cervical Cancer
- Interventions
- Bevacizumab, Cisplatin, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration, Topotecan Hydrochloride
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 541
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 351 more
- Conditions
- Ulcerative Colitis
- Interventions
- Mirikizumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,281 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 98
- States / cities
- Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 83 more
- Conditions
- Head and Neck Cancer
- Interventions
- cisplatin, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2031
- U.S. locations
- 259
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 196 more
- Conditions
- RESPIRATORY SYNCYTIAL VIRUS (RSV)
- Interventions
- RSVpreF 120 µg, RSVpreF 60 µg
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Palo Alto, California • Rolling Hills Estates, California + 12 more
- Conditions
- Pancreatic Cancer
- Interventions
- dipyridamole, fluorouracil, leucovorin calcium, mitomycin C
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2007
- U.S. locations
- 84
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
- Conditions
- Traumatic Brain Injury, Cognitive Impairment
- Interventions
- Rivastigmine Transdermal Patch
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 8
- States / cities
- San Diego, California • Miami, Florida • Tampa, Florida + 5 more
- Conditions
- Leukemia
- Interventions
- nelarabine
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 16 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 107
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 69 more
- Conditions
- Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Pemetrexed, Positron Emission Tomography
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1081
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 694 more
- Conditions
- Heart Failure
- Interventions
- Warfarin titrated to an INR of 2.5-3.0, Aspirin, Clopidogrel 75
- Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 1,587 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 79
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more
- Conditions
- Healthy Volunteers Sickle Cell Disease, Thalassemia
- Interventions
- Etavopivat, Digoxin, Pitavastatin, Metformin, Midazolam, Rosuvastatin
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Prostate Cancer
- Interventions
- bicalutamide, estramustine, etoposide, flutamide, goserelin, leuprolide, nilutamide, paclitaxel
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2011
- U.S. locations
- 91
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
- Conditions
- Methamphetamine Dependence
- Interventions
- Bupropion, Placebo
- Drug · Other
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 9 more
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- erlotinib hydrochloride
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 106
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
- Conditions
- Endometrial Serous Adenocarcinoma, Fallopian Tube Carcinoma, Malignant Female Reproductive System Neoplasm, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
- Interventions
- Comprehensive Geriatric Assessment, Questionnaire Administration
- Other
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 70 Years and older · Female only
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 392
- States / cities
- Birmingham, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 282 more
- Conditions
- Contraception
- Interventions
- MR-100A-01
- Drug
- Lead sponsor
- Mylan Technologies Inc.
- Industry
- Eligibility
- 16 Years and older · Female only
- Enrollment
- 1,320 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 96
- States / cities
- Mobile, Alabama • Mesa, Arizona • Phoenix, Arizona + 72 more
- Conditions
- Gout
- Interventions
- Pegloticase, Methotrexate
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 63 more